X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA PIRAMAL ENTERPRISES PLETHICO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -1.1 39.6 - View Chart
P/BV x 0.0 3.3 0.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PLETHICO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-17
PLETHICO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3952,095 18.8%   
Low Rs311,025 3.1%   
Sales per share (Unadj.) Rs604.4492.8 122.6%  
Earnings per share (Unadj.) Rs32.572.6 44.8%  
Cash flow per share (Unadj.) Rs51.394.7 54.2%  
Dividends per share (Unadj.) Rs021.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs473.6862.5 54.9%  
Shares outstanding (eoy) m34.08172.56 19.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.2 11.1%   
Avg P/E ratio x6.621.5 30.5%  
P/CF ratio (eoy) x4.216.5 25.2%  
Price / Book Value ratio x0.51.8 24.9%  
Dividend payout %028.9 0.0%   
Avg Mkt Cap Rs m7,262269,194 2.7%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m1,59617,939 8.9%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m20,59885,037 24.2%  
Other income Rs m3862,338 16.5%   
Total revenues Rs m20,98487,374 24.0%   
Gross profit Rs m2,81834,991 8.1%  
Depreciation Rs m6423,817 16.8%   
Interest Rs m1,59320,310 7.8%   
Profit before tax Rs m96913,202 7.3%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m-1382,281 -6.1%   
Profit after tax Rs m1,10712,520 8.8%  
Gross profit margin %13.741.1 33.2%  
Effective tax rate %-14.317.3 -82.7%   
Net profit margin %5.414.7 36.5%  
BALANCE SHEET DATA
Current assets Rs m18,87787,590 21.6%   
Current liabilities Rs m11,896185,578 6.4%   
Net working cap to sales %33.9-115.2 -29.4%  
Current ratio x1.60.5 336.2%  
Inventory Days Days3631 115.8%  
Debtors Days Days19848 416.1%  
Net fixed assets Rs m9,861108,523 9.1%   
Share capital Rs m341345 98.7%   
"Free" reserves Rs m12,331148,481 8.3%   
Net worth Rs m16,139148,826 10.8%   
Long term debt Rs m4,706144,957 3.2%   
Total assets Rs m33,146482,394 6.9%  
Interest coverage x1.61.7 97.4%   
Debt to equity ratio x0.31.0 29.9%  
Sales to assets ratio x0.60.2 352.5%   
Return on assets %8.16.8 119.7%  
Return on equity %6.98.4 81.5%  
Return on capital %12.312.0 102.8%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40215,001 29.3%   
Fx outflow Rs m3,1845,150 61.8%   
Net fx Rs m1,2199,851 12.4%   
CASH FLOW
From Operations Rs m2,437-100,393 -2.4%  
From Investments Rs m-6,265-24,202 25.9%  
From Financial Activity Rs m2,490135,705 1.8%  
Net Cashflow Rs m-1,33711,110 -12.0%  

Share Holding

Indian Promoters % 82.7 52.9 156.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 4.0 107.5%  
FIIs % 5.5 26.6 20.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 16.5 45.5%  
Shareholders   10,665 93,274 11.4%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  ASTRAZENECA PHARMA  BIOCON LTD  

Compare PLETHICO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS